Cargando…

B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy

Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linke...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Manzar, Ali, Sabeeha, Mohammad, Taj, Hasan, Gulam Mustafa, Yadav, Dharmendra Kumar, Hassan, Md. Imtaiyaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509036/
https://www.ncbi.nlm.nih.gov/pubmed/34638779
http://dx.doi.org/10.3390/ijms221910442
_version_ 1784582240000278528
author Alam, Manzar
Ali, Sabeeha
Mohammad, Taj
Hasan, Gulam Mustafa
Yadav, Dharmendra Kumar
Hassan, Md. Imtaiyaz
author_facet Alam, Manzar
Ali, Sabeeha
Mohammad, Taj
Hasan, Gulam Mustafa
Yadav, Dharmendra Kumar
Hassan, Md. Imtaiyaz
author_sort Alam, Manzar
collection PubMed
description Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linked with cancer. Bcl-2 has been identified as being over-expressed in several cancers. Bcl-2 is induced by protein kinases and several signaling molecules which stimulate cancer development. Identifying the important function played by Bcl-2 in cancer progression and development, and treatment made it a target related to therapy for multiple cancers. Among the various strategies that have been proposed to block Bcl-2, BH3-mimetics have appeared as a novel group of compounds thanks to their favorable effects on many cancers within several clinical settings. Because of the fundamental function of Bcl-2 in the regulation of apoptosis, the Bcl-2 protein is a potent target for the development of novel anti-tumor treatments. Bcl-2 inhibitors have been used against several cancers and provide a pre-clinical platform for testing novel therapeutic drugs. Clinical trials of multiple investigational agents targeting Bcl-2 are ongoing. This review discusses the role of Bcl-2 in cancer development; it could be exploited as a potential target for developing novel therapeutic strategies to combat various types of cancers. We further highlight the therapeutic activity of Bcl-2 inhibitors and their implications for the therapeutic management of cancer.
format Online
Article
Text
id pubmed-8509036
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85090362021-10-13 B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy Alam, Manzar Ali, Sabeeha Mohammad, Taj Hasan, Gulam Mustafa Yadav, Dharmendra Kumar Hassan, Md. Imtaiyaz Int J Mol Sci Review Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linked with cancer. Bcl-2 has been identified as being over-expressed in several cancers. Bcl-2 is induced by protein kinases and several signaling molecules which stimulate cancer development. Identifying the important function played by Bcl-2 in cancer progression and development, and treatment made it a target related to therapy for multiple cancers. Among the various strategies that have been proposed to block Bcl-2, BH3-mimetics have appeared as a novel group of compounds thanks to their favorable effects on many cancers within several clinical settings. Because of the fundamental function of Bcl-2 in the regulation of apoptosis, the Bcl-2 protein is a potent target for the development of novel anti-tumor treatments. Bcl-2 inhibitors have been used against several cancers and provide a pre-clinical platform for testing novel therapeutic drugs. Clinical trials of multiple investigational agents targeting Bcl-2 are ongoing. This review discusses the role of Bcl-2 in cancer development; it could be exploited as a potential target for developing novel therapeutic strategies to combat various types of cancers. We further highlight the therapeutic activity of Bcl-2 inhibitors and their implications for the therapeutic management of cancer. MDPI 2021-09-28 /pmc/articles/PMC8509036/ /pubmed/34638779 http://dx.doi.org/10.3390/ijms221910442 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alam, Manzar
Ali, Sabeeha
Mohammad, Taj
Hasan, Gulam Mustafa
Yadav, Dharmendra Kumar
Hassan, Md. Imtaiyaz
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
title B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
title_full B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
title_fullStr B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
title_full_unstemmed B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
title_short B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
title_sort b cell lymphoma 2: a potential therapeutic target for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509036/
https://www.ncbi.nlm.nih.gov/pubmed/34638779
http://dx.doi.org/10.3390/ijms221910442
work_keys_str_mv AT alammanzar bcelllymphoma2apotentialtherapeutictargetforcancertherapy
AT alisabeeha bcelllymphoma2apotentialtherapeutictargetforcancertherapy
AT mohammadtaj bcelllymphoma2apotentialtherapeutictargetforcancertherapy
AT hasangulammustafa bcelllymphoma2apotentialtherapeutictargetforcancertherapy
AT yadavdharmendrakumar bcelllymphoma2apotentialtherapeutictargetforcancertherapy
AT hassanmdimtaiyaz bcelllymphoma2apotentialtherapeutictargetforcancertherapy